Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Rhea-AI Summary

Cadrenal Therapeutics, a biopharmaceutical company, will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company, trading under the Nasdaq symbol CVKD, is developing tecarfarin, an advanced oral anticoagulant aimed at preventing heart attacks, strokes, and deaths from blood clots in patients with rare cardiovascular conditions. A webcasted presentation is scheduled for 12:30pm ET on May 30, 2024, accessible via the conference homepage or directly through a provided link. The presentation will be available for replay. Additionally, the company’s management will host virtual one-on-one meetings with investors throughout the event. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event.

Positive

• Cadrenal Therapeutics is developing tecarfarin, a novel anticoagulant targeting serious cardiovascular conditions.
• Participation in the Lytham Partners Spring 2024 Investor Conference increases company visibility.
• Webcast presentation on May 30, 2024, provides a platform to communicate progress and strategy to investors.
• Opportunity for one-on-one investor meetings can help build investor relations and attract potential investments.

Negative

• No new clinical data or financial updates were provided in the press release.
• The press release did not mention any recent milestones or achievements for tecarfarin.

PONTE VEDRA, Fla., May 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditions, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

Company Webcast
The webcasted presentation will take place at 12:30pm ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/cvkd/2082696. The webcast will also be available for replay following the event.

1×1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/.

ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions who require chronic anticoagulation. Tecarfarin has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib).  Tecarfarin also has orphan drug designation for the prevention of thrombosis and thromboembolism in patients with ventricular assist devices (VADs). Cadrenal is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.  

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com 

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-lytham-partners-spring-2024-investor-conference-on-may-30-2024-302153439.html

SOURCE Cadrenal Therapeutics, Inc.

FAQ

What is the ticker symbol for Cadrenal Therapeutics?

The ticker symbol for Cadrenal Therapeutics is CVKD.

When will Cadrenal Therapeutics present at the Lytham Partners Spring 2024 Investor Conference?

Cadrenal Therapeutics will present on May 30, 2024, at 12:30pm ET.

What is Cadrenal Therapeutics developing?

Cadrenal Therapeutics is developing tecarfarin, a novel oral anticoagulant.

How can I access the webcast presentation by Cadrenal Therapeutics?

The webcast can be accessed via the conference homepage or directly through a provided link.

Can I arrange a one-on-one meeting with Cadrenal Therapeutics during the conference?

Yes, you can arrange a one-on-one meeting by contacting Lytham Partners or registering for the event.